Masimo (NASDAQ:MASI) Given Hold Rating at Needham & Company LLC

Needham & Company LLC reaffirmed their hold rating on shares of Masimo (NASDAQ:MASI) in a research report report published on Wednesday morning,Benzinga reports.

A number of other equities analysts also recently weighed in on MASI. Raymond James raised their target price on shares of Masimo from $170.00 to $194.00 and gave the company an “outperform” rating in a research note on Friday, December 27th. Wells Fargo & Company raised their price objective on Masimo from $171.00 to $193.00 and gave the company an “overweight” rating in a research report on Wednesday, December 11th. Piper Sandler boosted their target price on Masimo from $180.00 to $210.00 and gave the stock an “overweight” rating in a report on Wednesday, December 18th. BTIG Research raised their price target on Masimo from $166.00 to $170.00 and gave the company a “buy” rating in a report on Monday, October 14th. Finally, Stifel Nicolaus reaffirmed a “buy” rating and issued a $190.00 price target (up previously from $170.00) on shares of Masimo in a research report on Friday, November 22nd. Three equities research analysts have rated the stock with a hold rating and five have given a buy rating to the stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $179.67.

Masimo Trading Down 1.7 %

NASDAQ MASI opened at $173.16 on Wednesday. The firm has a market capitalization of $9.27 billion, a PE ratio of 119.42 and a beta of 1.01. The stock’s 50 day moving average is $169.75 and its 200 day moving average is $141.35. Masimo has a twelve month low of $101.61 and a twelve month high of $180.97. The company has a quick ratio of 1.11, a current ratio of 2.01 and a debt-to-equity ratio of 0.50.

Masimo (NASDAQ:MASI) last announced its earnings results on Tuesday, November 5th. The medical equipment provider reported $0.98 EPS for the quarter, beating analysts’ consensus estimates of $0.84 by $0.14. The firm had revenue of $504.60 million for the quarter, compared to analysts’ expectations of $502.87 million. Masimo had a net margin of 3.85% and a return on equity of 14.98%. The company’s quarterly revenue was up 5.4% on a year-over-year basis. During the same quarter in the previous year, the business posted $0.63 EPS. Research analysts forecast that Masimo will post 4.1 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Masimo

A number of hedge funds have recently bought and sold shares of the business. ING Groep NV grew its stake in shares of Masimo by 143.3% in the third quarter. ING Groep NV now owns 240,900 shares of the medical equipment provider’s stock worth $32,119,000 after acquiring an additional 141,900 shares during the period. Westfield Capital Management Co. LP grew its position in Masimo by 23.2% in the 3rd quarter. Westfield Capital Management Co. LP now owns 1,394,056 shares of the medical equipment provider’s stock worth $185,869,000 after purchasing an additional 262,370 shares during the period. National Bank of Canada FI raised its stake in Masimo by 195.6% during the 3rd quarter. National Bank of Canada FI now owns 132,500 shares of the medical equipment provider’s stock valued at $17,666,000 after buying an additional 87,675 shares during the last quarter. SG Americas Securities LLC bought a new position in shares of Masimo during the 3rd quarter valued at $3,862,000. Finally, Oppenheimer Asset Management Inc. purchased a new position in shares of Masimo in the 3rd quarter worth $478,000. Hedge funds and other institutional investors own 85.96% of the company’s stock.

About Masimo

Masimo Corporation develops, manufactures, and markets various patient monitoring technologies, and automation and connectivity solutions worldwide. The company offers masimo signal extraction technology (SET) pulse oximetry with measure-through motion and low perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry; Masimo rainbow SET platform, including rainbow SET Pulse CO-Oximetry products that allows noninvasive monitoring of carboxyhemoglobin, methemoglobin, hemoglobin concentration, fractional arterial oxygen saturation, oxygen content, pleth variability index, rainbow pleth variability index, respiration rate from the pleth, and oxygen reserve index, as well as acoustic respiration monitoring, SedLine brain function monitoring, NomoLine capnography and gas monitoring, and regional oximetry.